Skip to main content

Find Clinical Trials

Home
Conditions
Neoplasms, Plasma Cell

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,639 public trials 556 recruiting studies

Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Recruiting

CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

NCT07652905

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

NCT07382739

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Elranatamab, +19 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

NCT07210047

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Far Eastern Memorial Hospital Taipei, Taiwan

View Trial Details

Recruiting

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

NCT07623798

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations: ZhongShan Hospital FuDan University Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

NCT07585760

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, China

View Trial Details

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: City of Hope Duarte, California, United States

City of Hope - Lennar Foundation Cancer Center Irvine, California, United States

Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center Denver, Colorado, United States

Karmanos Cancer Institute. Detroit, Michigan, United States

View all 34 locations

View Trial Details

Recruiting

A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

NCT07760454

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China

Renji Hospital,Shanghai Jiao Tong University School Of Medicine Shanghai, China

View Trial Details

Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

NCT07825064

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Universitätsklinikum Jena, Klinik für Innere Medizin II Jena, Germany

View Trial Details

Recruiting

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

NCT05892393

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Recruiting

A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis

NCT07215494

Conditions: Amyloidosis, Immune System Diseases, Immunoglobulin Light-chain Amyloidosis, +11 more
Locations: Peking University First Hospital Beijing, Beijing Municipality, China

View Trial Details